Free Newsletter
Woman's immune system may be key to HIV vax
An investigative team at Johns Hopkins has been studying a woman whose natural immunity has quelled the virus she was infected with 10 years ago. Researchers say that she is an 'elite suppressor:' her immune cells could hold the key to solving the vexing riddle of creating a vaccine for HIV.
"This is an extremely rare case of co-infection in a controlled, monogamous relationship, which showed us how a strong immune system in the elite suppressor kept the virus from replicating and infecting other cells," said Joel Blankson, the senior study investigator and infectious disease specialist.
The woman's CD-8 T cells were able to stall roughly 90 percent of HIV replication, a duplicate of the virus that affects her husband. The researchers want to learn what kind of cytokines--immune system signaling proteins--are made by her T cells. They are also interested in learning more about why they're seeing odd activity in her human leukocyte antigen system.
- check out the press release
Related Articles:
HIV research summit seeks new discovery path
Feds steering funds back to basic AIDS vax research
AIDS scientist backed on new vaccine approach
Fauci says HIV vaccine requires a new approach
Comments
That is such a cute article,
" Woman's immune system may be key to HIV vax."
Lets do a follow up in 15 years.
It a shame these scientist throw the word controller around so easily. I was told Johns Hopkins was still 10 years behind all other groups.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: